0000947871-21-001314.txt : 20211223
0000947871-21-001314.hdr.sgml : 20211223
20211223160854
ACCESSION NUMBER: 0000947871-21-001314
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211221
FILED AS OF DATE: 20211223
DATE AS OF CHANGE: 20211223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thompson Peter A.
CENTRAL INDEX KEY: 0001357522
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40475
FILM NUMBER: 211517234
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
FORMER NAME:
FORMER CONFORMED NAME: Thompson Peter A
DATE OF NAME CHANGE: 20060327
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Janux Therapeutics, Inc.
CENTRAL INDEX KEY: 0001817713
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822289112
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11099 TORREY PINES PARK ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-750-4700
MAIL ADDRESS:
STREET 1: 11099 TORREY PINES PARK ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92037
4
1
ownership.xml
X0306
4
2021-12-21
0
0001817713
Janux Therapeutics, Inc.
JANX
0001357522
Thompson Peter A.
C/O JANUX THERAPEUTICS, INC.
11099 N. TORREY PINES ROAD, SUITE 290
LA JOLLA
CA
92037
1
0
0
0
Common Stock
2021-12-21
4
S
0
108300
19.00
D
2295266
I
See Footnotes
Common Stock
2021-12-21
4
S
0
11100
19.00
D
234798
I
See Footnotes
These shares of the Issuer's common stock were sold in a block order at a price of $19.00.
These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis.
Each of the Reporting Person, OrbiMed Advisors, GP VIII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
/s/ Peter Thompson
2021-12-23